Affect of swimming train on the expression
Have an effect on of swimming prepare on the expression of apoptotic gene caspase-Three in chondrocytes in osteoarthritis
Objective: To assessment swimming prepare’s influence on caspase-3 expression in chondrocytes in osteoarthritis (OA).
Methods: 36 SD rats had been randomly separated into common group (n = 12), OA model group (n = 12) and swimming prepare group (n = 12). After modeling, rats obtained no intervention in model group and swimming prepare as quickly as a day (15 min/time) for 4 consecutive weeks in swimming prepare group. After intervention for 4 weeks, specimens had been taken to analysis tissue morphology by H&E staining, caspase-Three expression by Western blot and qPCR, chondrocytes apoptosis by TUNEL assay.
Outcomes: HE staining revealed irregular bone tissue morphology in model group and swimming prepare group with improved morphology after swimming prepare. Model group and swimming prepare group all confirmed significantly bigger Caspase-Three protein diploma than common group with lower diploma after swimming prepare (P < 0.05). Persistently, qPCR confirmed comparable expression profile of caspase-Three mRNA diploma to the protein diploma.
Anti-Murine Panendothelial Cell Antigen (MECA-32) Antibody |
|||
| MBS4158532-5x01mg | MyBiosource | 5x0.1mg | EUR 3880 |
Mouse Anti-Hepatitis B Surface Antigen Antibody (1834) |
|||
| MAB12230-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1834). |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1837) |
|||
| MAB12231-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1837) |
|||
Mouse Anti-Hepatitis B Surface Antigen Antibody (1838) |
|||
| MAB12232-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus surface antigen (1838) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1892) |
|||
| MAB12226-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1892) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1893) |
|||
| MAB12227-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1893) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (1894) |
|||
| MAB12228-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (1894) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M132) |
|||
| MAB12298-500 | The Native Antigen Company | 0.5 | EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M132) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
Mouse Anti-Hepatitis B Virus E Antigen Antibody (M133) |
|||
| MAB12299-500 | The Native Antigen Company | 0.5 | EUR 695.29 |
|
Description: Mouse monoclonal antibody specific for Hepatitis B virus e antigen (M133) |
|||
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (AP) |
|||
| MBS6248246-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (AP) |
|||
| MBS6248246-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (HRP) |
|||
| MBS6251180-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (HRP) |
|||
| MBS6251180-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (PE) |
|||
| MBS6252121-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (PE) |
|||
| MBS6252121-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (FITC) |
|||
| MBS6250161-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (FITC) |
|||
| MBS6250161-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAPC (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (APC) |
|||
| MBS6269097-01mL | MyBiosource | 0.1mL | EUR 860 |
PLVAPC (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (APC) |
|||
| MBS6269097-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 490) |
|||
| MBS6254194-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 490) |
|||
| MBS6254194-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 550) |
|||
| MBS6255234-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 550) |
|||
| MBS6255234-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 405) |
|||
| MBS6253154-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 405) |
|||
| MBS6253154-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 750) |
|||
| MBS6257313-01mL | MyBiosource | 0.1mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 750) |
|||
| MBS6257313-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 650) |
|||
| MBS6256274-01mL | MyBiosource | 0.1(mL | EUR 860 |
PLVAP (Plasmalemma Vesicle-Associated Protein, Plasmalemma Vesicle Protein 1, PV-1, MECA-32 Antigen, Pv1) (MaxLight 650) |
|||
| MBS6256274-5x01mL | MyBiosource | 5x0.1mL | EUR 3720 |
Rat Anti-Mouse MAdCAM-1 Monoclonal antibody, clone MECA-367 |
|||
| CABT-L4373-1mg | Creative Diagnostics | 1 mg | EUR 1076.4 |
Rat Anti-Mouse MAdCAM-1 Monoclonal antibody, clone MECA-367 |
|||
| CABT-L4373-5mg | Creative Diagnostics | 5 mg | EUR 2886 |
Rat Anti-Mouse MAdCAM-1 Monoclonal antibody, clone MECA-367 |
|||
| CABT-L4373 | Creative Diagnostics | 1 mg; 5 mg | Ask for price |
|
Description: Rat |
|||
Borrelia Afzelii Antigen |
|||
| NAT41583-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Afzelii Antigen |
|||
| NAT41583-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Garinii Antigen |
|||
| NAT41584-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Borrelia Garinii Antigen |
|||
| NAT41584-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Harvested bacteria are washed and detergent solubilized to produce a cytoplasmic extract enriched with lipoproteins and outer surface proteins (OSPs). The antigen is presented in phosphate buffered saline containing 1 % n-octyl-β-D-glucopyranoside. |
|||
Brucella Abortus Antigen |
|||
| NAT41599-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Brucella abortus lysate, produced by fermentation. |
|||
Brucella Abortus Antigen |
|||
| NAT41599-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Brucella abortus lysate, produced by fermentation. |
|||
Candida Albicans Antigen |
|||
| NAT41601-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Candida Albicans Antigen |
|||
| NAT41601-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Candida albicans is grown on solid medium, washed, disrupted and subjected to an extraction process. The antigen consists of cytoplasmic and cell wall components. |
|||
Canine Parvovirus Antigen |
|||
| NAT41594-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Parvovirus, produced in CRFK cells. |
|||
Canine Coronavirus Antigen |
|||
| NAT41590-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Coronavirus produced in A-72 cells. |
|||
Feline Calicivirus Antigen |
|||
| NAT41595-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Calicivirus produced in FC 3TG cells. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Helicobacter Pylori Antigen |
|||
| NAT41603-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Bacteria are cultured on solid medium, harvested, washed and solubilised. The antigen is partially purified by detergent extraction and centrifugation. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
Campylobacter Jejuni Antigen |
|||
| NAT41600-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Campylobacter jejuni is cultured on solid medium. This antigen is a partially purified detergent extract of the membrane fraction. The main component is an outer membrane protein, approximately 45 kDa in SDS-PAGE. |
|||
Chlamydia Trachomatis Antigen |
|||
| CT022-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
|
Description: Chlamydia trachomatis antigens from clarified cell lysate. |
|||
Neisseria Gonorrhoeae Antigen |
|||
| NG01-1000 | The Native Antigen Company | 1.0 | EUR 378.9 |
|
Description: Homogenised lysate of pure bacteria. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-1000 | The Native Antigen Company | 1.0 | EUR 1010.39 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Mycoplasma Pneumoniae Antigen |
|||
| MP901-200 | The Native Antigen Company | 0.2 | EUR 270.46 |
|
Description: Mycoplasma pneumoniae whole organisms that have been purified and detergent treated to enrich antigenic proteins and decrease background. |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Echovirus Antigen, Recombinant |
|||
| REC31776-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus |
|||
Trichomonas Vaginalis Antigen |
|||
| TV01-1000 | The Native Antigen Company | 1.0 | EUR 421 |
|
Description: Washed & lysed suspension of whole protozoa |
|||
Echinococcus Granulosus Antigen |
|||
| NAT41602-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Echinococcus Granulosus Antigen |
|||
| NAT41602-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Echinococcus granulosus material is derived from bovine hydatid cyst as sterile filtered cyst fluid. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-100 | The Native Antigen Company | 0.1 | EUR 276.84 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Enterovirus Antigen, Recombinant |
|||
| REC31772-500 | The Native Antigen Company | 0.5 | EUR 1043.56 |
|
Description: Proprietary recombinant antigen expressed in E. coli and purified by chromatography. Individually pooled antigens shown to react with QC serum panel (multiple negative, borderline and positive sera) within defined reactivity range in Coxsackie-/Echovirus IgA, IgG and IgM ELISA. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-1000 | The Native Antigen Company | 1.0 | EUR 1654.65 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Astrovirus Antigen (Type 1) |
|||
| AS02-200 | The Native Antigen Company | 0.2 | EUR 442.69 |
|
Description: A concentrated source of Astrovirus particles and Astrovirus proteins from a lysate of host cells. |
|||
Yersinia pestis V antigen |
|||
| REC32028-100 | The Native Antigen Company | 0.1 | EUR 491.53 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Yersinia pestis V antigen |
|||
| REC32028-500 | The Native Antigen Company | 0.5 | EUR 2421.37 |
|
Description: Yersinia pestis V antigen (LcrV antigen, capsule protein fraction 1, type III secretion system needle tip protein). The protein is produced as an N-terminal GST fusion, with GST being cleaved by thrombin and is not present in the final product. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-100 | The Native Antigen Company | 0.1 | EUR 318.94 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-1000 | The Native Antigen Company | 1.0 | EUR 2096.06 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Cytomegalovirus Purified Antigen |
|||
| CMV-HP-500 | The Native Antigen Company | 0.5 | EUR 1279.58 |
|
Description: A concentrated source of human Cytomegalovirus particles purified by sucrose gradient ultracentrifugation. |
|||
Canine Herpes Virus Antigen |
|||
| NAT41592-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Herpes virus, produced in MDCK cells. |
|||
Canine Adenovirus 1 Antigen |
|||
| NAT41587-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Adenovirus Type 1, produced in A-72 cells. |
|||
Canine Adenovirus 2 Antigen |
|||
| NAT41588-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Adenovirus Type 2, produced in A-72 cells. |
|||
Canine Distemper Virus Antigen |
|||
| NAT41591-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Distemper virus, produced in SL-29 cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-100 | The Native Antigen Company | 0.1 | EUR 302.36 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-1000 | The Native Antigen Company | 1.0 | EUR 1830.71 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Norovirus GII.4 VP1 Antigen |
|||
| REC31620-500 | The Native Antigen Company | 0.5 | EUR 1066.53 |
|
Description: Recombinant Norovirus GII.4 VP1 antigen produced in 293 human cells. |
|||
Canine Parainfluenza Virus Antigen |
|||
| NAT41593-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Canine Parainfluenza virus antigen, produced in MDCK cells. |
|||
Feline Panleukopenia Virus Antigen |
|||
| NAT41597-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Panleukopenia Virus (FPLV; feline parvovirus) antigen, produced in CRFK cells. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-100 | The Native Antigen Company | 0.1 | EUR 223.26 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Cytomegalovirus Cell Lysate Antigen |
|||
| CMV-CL-1000 | The Native Antigen Company | 1.0 | EUR 1422.47 |
|
Description: A clarified cell lysate containing a mix of CMV antigens from all stages of the replication life cycle. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 1 Antigen |
|||
| HS105-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
|
Description: HSV-1 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-1000 | The Native Antigen Company | 1.0 | EUR 1178.79 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Herpes Simplex Virus 2 Antigen |
|||
| HS205-200 | The Native Antigen Company | 0.2 | EUR 294.7 |
|
Description: HSV-2 particles from a cell lysate are purified by sucrose gradient ultracentrifugation. |
|||
Feline Viral Rhinotracheitis Antigen |
|||
| NAT41598-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Viral Rhinotracheitis (FVR; feline herpes virus, FHV-1) antigen, produced in CRFK cells. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-100 | The Native Antigen Company | 0.1 | EUR 757.8 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Ross River Virus Recombinant Antigen |
|||
| REC31969-500 | The Native Antigen Company | 0.5 | EUR 2844.92 |
|
Description: Recombinant Ross River virus antigen expressed in HEK293 cells as virus-like particles and purified by sucrose density gradients and precipitation. Virus-like particles were then solubilized in PBS containing 0.2% SDS to prevent aggregation of particles. The preparation is not particulate. Antigens in the preparation include Envelope proteins 1 and 2 and Nucleoprotein. |
|||
Canine Adenovirus 1 and 2 Antigen |
|||
| NAT41589-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: A mixture of Canine Adenovirus Type 1 and Type 2, produced in A-72 cells. |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus E Antigen (HBeAg) |
|||
| REC31677-500 | The Native Antigen Company | 0.5 | EUR 1941.06 |
|
Description: Recombinant Hepititis B Virus E Protein (HBeAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-100 | The Native Antigen Company | 0.1 | EUR 456.72 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis B Virus Core Antigen (HBcAg) |
|||
| REC31689-500 | The Native Antigen Company | 0.5 | EUR 1370.16 |
|
Description: Recombinant Hepititis B Virus Core Protein (HBcAg). |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-100 | The Native Antigen Company | 0.1 | EUR 484.79 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Hepatitis C Virus Core Antigen (HCcAg) |
|||
| REC31693-500 | The Native Antigen Company | 0.5 | EUR 1455.64 |
|
Description: Recombinant Hepatitis C Virus core protein is produced in E. coli and fused with a His-tag. |
|||
Herpes Simplex Virus 1 Lysate Antigen |
|||
| HS104-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
|
Description: A high concentration of HSV-1 particles and proteins from a clarified cell lysate. |
|||
Herpes Simplex Virus 2 Lysate Antigen |
|||
| HS204-1000 | The Native Antigen Company | 1.0 | EUR 270.46 |
|
Description: A high concentration of HSV-2 particles and proteins from a clarified cell lysate. |
|||
Feline Infectious Peritonitis Virus Antigen |
|||
| NAT41596-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Feline Infectious Peritonitis virus (FIPV; feline coronavirus) antigen, produced in CRFK cells. |
|||
Legionella pneumophila antigen (native extract) |
|||
| NAT41580-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Legionella pneumophila antigen from culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Leptospira Biflexa Antigen (Strain Patoc 1) |
|||
| NAT41582-500 | The Native Antigen Company | 0.5 | EUR 1176.24 |
|
Description: Inactivated Leptospira biflexa antigen (Strain Patoc 1) from broth culture. |
|||
Streptococcus Pneumoniae Antigen, Native Extract |
|||
| NAT41604-100 | The Native Antigen Company | 0.1 | EUR 391.66 |
|
Description: Inactivated Streptococcus pneumoniae antigen from culture. |
|||
Mouse Anti-Giardia Monoclonal Antibody (E4) |
|||
| MAB12477-100 | The Native Antigen Company | 0.1 | EUR 395.48 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
Mouse Anti-Giardia Monoclonal Antibody (E4) |
|||
| MAB12477-500 | The Native Antigen Company | 0.5 | EUR 1678.89 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
Mouse Anti-Giardia Monoclonal Antibody (E11) |
|||
| MAB12478-100 | The Native Antigen Company | 0.1 | EUR 395.48 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
Mouse Anti-Giardia Monoclonal Antibody (E11) |
|||
| MAB12478-500 | The Native Antigen Company | 0.5 | EUR 1678.89 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
Mouse Anti-Giardia Monoclonal Antibody (G203) |
|||
| MAB12479-100 | The Native Antigen Company | 0.1 | EUR 447.93 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
Mouse Anti-Giardia Monoclonal Antibody (G203) |
|||
| MAB12479-500 | The Native Antigen Company | 0.5 | EUR 1678.89 |
|
Description: This antibody recognises the Cyst-Wall-Protein-1 (CWP1) antigen on the surface of Giardia cysts. |
|||
MOUSE ANTI MOUSE NK-1.1 ANTIGEN |
|||
| MBS212065-025mg | MyBiosource | 0.25mg | EUR 500 |
MOUSE ANTI MOUSE NK-1.1 ANTIGEN |
|||
| MBS212065-5x025mg | MyBiosource | 5x0.25mg | EUR 2070 |
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-100 | The Native Antigen Company | 0.1 | EUR 491.53 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Yersinia pestis chain B F1 capsule antigen, C-terminal His-tag |
|||
| REC32027-500 | The Native Antigen Company | 0.5 | EUR 2421.37 |
|
Description: Yersinia pestis chain B F1 capsule antigen (Antig_Caf1) |
|||
Mouse Anti-Giardia Lamblia Trophozoite Antibody (G18) |
|||
| MAB12153-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Giardia lamblia trophoziote protein (clone G18) |
|||
Mouse Anti-Giardia Lamblia Trophozoite Antibody (G22) |
|||
| MAB12154-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Giardia lamblia trophoziote protein (clone G22) |
|||
Mouse Anti-Hepatitis D Antigen (Delta Virus Antigen) |
|||
| MBS6506734-1mg | MyBiosource | 1mg | EUR 785 |
Mouse Anti-Hepatitis D Antigen (Delta Virus Antigen) |
|||
| MBS6506734-5x1mg | MyBiosource | 5x1mg | EUR 3305 |
MECA-79 Antibody / Peripheral Node Addressin / PNAd |
|||
| V8344-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
|
Description: MECA-79 recognizes a carbohydrate epitope shared with a group of sulfation decorated sialomucins, including sulfated ligands for CD62L (CD34, GlyCAM-1, Sgp200, and a subset of MAdCAM-1). This set antigens has been referred to as peripheral node addressin (PNAd) with the molecular mass 50-250 kD. It has been identified that GlcNAc-6-SO4 sulfation contributes to MECA-79 binding and the core 1 beta1,3-N-acetylglucosaminyltransferase is required for the generation of the MECA-79 epitope. MECA-79 is expressed on high endothelial venules (HEV) of lymphoid tissues, chronic inflamed tissues and rheumatoid synovia. The interaction of PNAd with CD62L receptor is involved in tethering and rolling of lymphocytes along HEV in lymphoid tissues. MECA-79 antibody reacts with Mouse, human and many other species PNAd and blocks L-selectin-dependent lymphocyte adhesion in vitro and in vivo. |
|||
MECA-79 Antibody / Peripheral Node Addressin / PNAd |
|||
| V8344-20UG | NSJ Bioreagents | 20 ug | EUR 186.15 |
|
Description: MECA-79 recognizes a carbohydrate epitope shared with a group of sulfation decorated sialomucins, including sulfated ligands for CD62L (CD34, GlyCAM-1, Sgp200, and a subset of MAdCAM-1). This set antigens has been referred to as peripheral node addressin (PNAd) with the molecular mass 50-250 kD. It has been identified that GlcNAc-6-SO4 sulfation contributes to MECA-79 binding and the core 1 beta1,3-N-acetylglucosaminyltransferase is required for the generation of the MECA-79 epitope. MECA-79 is expressed on high endothelial venules (HEV) of lymphoid tissues, chronic inflamed tissues and rheumatoid synovia. The interaction of PNAd with CD62L receptor is involved in tethering and rolling of lymphocytes along HEV in lymphoid tissues. MECA-79 antibody reacts with Mouse, human and many other species PNAd and blocks L-selectin-dependent lymphocyte adhesion in vitro and in vivo. |
|||
MECA-79 Antibody / Peripheral Node Addressin / PNAd |
|||
| V8344SAF-100UG | NSJ Bioreagents | 100 ug | EUR 424.15 |
|
Description: MECA-79 recognizes a carbohydrate epitope shared with a group of sulfation decorated sialomucins, including sulfated ligands for CD62L (CD34, GlyCAM-1, Sgp200, and a subset of MAdCAM-1). This set antigens has been referred to as peripheral node addressin (PNAd) with the molecular mass 50-250 kD. It has been identified that GlcNAc-6-SO4 sulfation contributes to MECA-79 binding and the core 1 beta1,3-N-acetylglucosaminyltransferase is required for the generation of the MECA-79 epitope. MECA-79 is expressed on high endothelial venules (HEV) of lymphoid tissues, chronic inflamed tissues and rheumatoid synovia. The interaction of PNAd with CD62L receptor is involved in tethering and rolling of lymphocytes along HEV in lymphoid tissues. MECA-79 antibody reacts with Mouse, human and many other species PNAd and blocks L-selectin-dependent lymphocyte adhesion in vitro and in vivo. |
|||
Anti-La Antigen Mouse mAb |
|||
| E2201300 | EnoGene | 100ul | EUR 225 |
|
Description: Available in various conjugation types. |
|||
Anti-La Antigen Mouse mAb |
|||
| MBS8533223-01mL | MyBiosource | 0.1mL | EUR 305 |
Anti-La Antigen Mouse mAb |
|||
| MBS8533223-01mLAF405L | MyBiosource | 0.1mL(AF405L) | EUR 565 |
Anti-La Antigen Mouse mAb |
|||
| MBS8533223-01mLAF405S | MyBiosource | 0.1mL(AF405S) | EUR 565 |
Anti-La Antigen Mouse mAb |
|||
| MBS8533223-01mLAF610 | MyBiosource | 0.1mL(AF610) | EUR 565 |
Anti-La Antigen Mouse mAb |
|||
| MBS8533223-01mLAF635 | MyBiosource | 0.1mL(AF635) | EUR 565 |
Anti-La Antigen Mouse mAb |
|||
| MBS475587-01mL | MyBiosource | 0.1mL | EUR 450 |
Anti-La Antigen Mouse mAb |
|||
| MBS475587-5x01mL | MyBiosource | 5x0.1mL | EUR 1540 |
Mouse anti Carcinoma ass. Antigen |
|||
| MBS570279-01mg | MyBiosource | 0.1mg | EUR 515 |
Mouse anti Carcinoma ass. Antigen |
|||
| MBS570279-5x01mg | MyBiosource | 5x0.1mg | EUR 2165 |
MOUSE ANTI HUMAN NUCLEAR ANTIGEN |
|||
| MBS211180-01mL | MyBiosource | 0.1mL | EUR 605 |
MOUSE ANTI HUMAN NUCLEAR ANTIGEN |
|||
| MBS211180-5x01mL | MyBiosource | 5x0.1mL | EUR 2555 |
PLVAP rat monoclonal antibody, clone MECA-32, Biotin |
|||
| AM05595BT-N | Origene Technologies GmbH | 100 µg | Ask for price |
PLVAP rat monoclonal antibody, clone MECA-32, Purified |
|||
| AM05595PU-L | Origene Technologies GmbH | 250 µg | Ask for price |
PLVAP rat monoclonal antibody, clone MECA-32, Purified |
|||
| AM05595PU-N | Origene Technologies GmbH | 100 µg | Ask for price |
PLVAP rat monoclonal antibody, clone MECA-32, Purified |
|||
| AM05595PU-T | Origene Technologies GmbH | 25 µg | Ask for price |
MOUSE ANTI ANTHRAX PROTECTIVE ANTIGEN |
|||
| MBS214545-02mg | MyBiosource | 0.2mg | EUR 515 |
MOUSE ANTI ANTHRAX PROTECTIVE ANTIGEN |
|||
| MBS214545-5x02mg | MyBiosource | 5x0.2mg | EUR 2145 |
Mouse Anti-Adenovirus Antibody (A68) |
|||
| MAB12508-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A68). |
|||
Mouse Anti-Adenovirus Antibody (A68) |
|||
| MAB12508-500 | The Native Antigen Company | 0.5 | EUR 964.47 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A68). |
|||
Mouse Anti-Adenovirus Antibody (A93) |
|||
| MAB12509-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A93). |
|||
Mouse Anti-Adenovirus Antibody (A93) |
|||
| MAB12509-500 | The Native Antigen Company | 0.5 | EUR 964.47 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A93). |
|||
Mouse anti Melanoma Associated Antigen |
|||
| MBS570200-01mg | MyBiosource | 0.1mg | EUR 515 |
Mouse anti Melanoma Associated Antigen |
|||
| MBS570200-5x01mg | MyBiosource | 5x0.1mg | EUR 2165 |
Mouse anti Melanoma Associated Antigen |
|||
| MBS570274-01mg | MyBiosource | 0.1mg | EUR 515 |
Mouse anti Melanoma Associated Antigen |
|||
| MBS570274-5x01mg | MyBiosource | 5x0.1mg | EUR 2165 |
MECA-79(MECA-79), 0.2mg/mL |
|||
| BNUB1599-100 | Biotium | 1uL | EUR 225 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MECA-79(MECA-79), 0.2mg/mL |
|||
| BNUB1599-500 | Biotium | 1uL | EUR 485 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
MECA-79(MECA-79), 1mg/mL |
|||
| BNUM1599-50 | Biotium | 1uL | EUR 396 |
|
Description: Primary and secondary antibodies for multiple methodologyimmunostaining detection application |
|||
Mouse Anti-Astrovirus Antibody (AT54) |
|||
| MAB12138-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Astrovirus (clone AT54) |
|||
Mouse Anti-Adenovirus Antibody (A114) |
|||
| MAB12510-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A114). |
|||
Mouse Anti-Adenovirus Antibody (A114) |
|||
| MAB12510-500 | The Native Antigen Company | 0.5 | EUR 964.47 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A114). |
|||
Mouse Anti-Adenovirus Antibody (A115) |
|||
| MAB12511-100 | The Native Antigen Company | 0.1 | EUR 275.56 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A115). |
|||
Mouse Anti-Adenovirus Antibody (A115) |
|||
| MAB12511-500 | The Native Antigen Company | 0.5 | EUR 964.47 |
|
Description: Mouse monoclonal antibody specific for Adenovirus (clone A115). |
|||
Allium jesdianum hydro alcoholic extract ameliorates diabetic nephropathy by suppressing connective tissue improvement situation (CTGF) and receptor for superior glycation endproducts (RAGE) gene expression in diabetic rats with streptozotocin
Objectives: Diabetic nephropathy is taken into account one among the foremost issues of diabetes, the utilization of medicinal vegetation is rising due to fewer destructive results. This study was designed to take a look at antidiabetic outcomes of Allium jesdianum (A. jesdianum) ethanolic extract and take into account its outcomes on oxidative stress markers and the expression of connective tissue improvement situation (CTGF) and receptor for superior glycation endproducts (RAGE) genes throughout the kidney of kind 1 diabetic rats.
Methods: On this study, we randomly divided 24 rats into four groups with six rats in each group as follows: Cnt group: common administration receiving common saline, Dibt group: diabetic administration receiving common saline day by day, Dibt + A. jesdianum 250 group: diabetic rats receiving A. jesdianum at a dose of 250 mg/kg bw day by day, Dibt + A. jesdianum 500 group: diabetic rats receiving A. jesdianum at a dose of 500 mg/kg bw day by day. To induce diabetes, we used 55 mg/kg bw dose of streptozotocin intraperitoneally. The main focus of fasting blood glucose (FBG) and serum urea, creatinine and albumin, SOD, MDA (using spectrophotometric methods) and gene expression of CTGF and RAGE in kidney tissue (using real-time PCR methods) had been quantified throughout the diabetic rats that obtained A. jesdianum for 42 days, and had been as compared with administration rats.
Outcomes: The outcomes confirmed that in the diabetic group the FBG and serum urea, creatinine and expression of kidney CTGF and RAGE genes and the levels of SOD and MDA significantly elevated and serum albumin significantly decreased as compared with the Cnt group (p<0.001). Administration of A. jesdianum significantly improved the FBG and serum urea, creatinine and albumin as compared with Dibt group (p<0.05). It was confirmed the A. jesdianum significantly decrease the kidney expression ranges of CTGF and RAGE genes and improve oxidative stress (elevated SOD and decreased MDA) throughout the kidney tissues when as compared with Dibt group (p<0.001). Moreover, it was found that the helpful outcomes of the A. jesdianum had been dose-dependent.
Conclusions: The outcomes of this study confirmed that administration of A. jesdianum for 42 days has helpful anti-diabetic and anti-nephropathic ends in diabetic rats and may be utilized as an adjunct treatment throughout the treatment of diabetes.
The interplay of oxidative stress and ARMS2-HTRA1 genetic hazard in neovascular AMD
Age-related macular degeneration (AMD) is the principle purpose for imaginative and prescient loss in adults over 60 years earlier globally. There are two kinds of superior AMD: “dry” and “moist”. Dry AMD is characterised by geographic atrophy of the retinal pigment epithelium and overlying photoreceptors throughout the macular space; whereas moist AMD is characterised by vascular penetrance from the choroid into the retina, typically generally known as choroidal neovascularization (CNV). Every phenotypes lastly end in lack of central imaginative and prescient. The pathogenesis of AMD consists of the interplay of genetic polymorphisms and environmental hazard parts, quite a lot of which elevate retinal oxidative stress.
Further reactive oxygen species react with cellular macromolecules, forming oxidation-modified byproducts that elicit continuous irritation and promote CNV. Furthermore, genome-wide affiliation analysis have acknowledged a variety of genetic variants throughout the age-related maculopathy susceptibility 2/high-temperature requirement A serine peptidase 1 (ARMS2-HTRA1) locus associated to the event of late-stage AMD, significantly the moist subtype. On this consider, we’re going to cope with the interplay of oxidative stress and HTRA1 in drusen deposition, continuous irritation, and continuous angiogenesis. We intention to present a multifactorial model of moist AMD improvement, supporting HTRA1 as a novel therapeutic objective upstream of vascular endothelial improvement situation (VEGF), the usual objective in AMD therapeutics. By inhibiting HTRA1’s proteolytic train, we’re in a position to reduce pro-angiogenic signaling and forestall proteolytic breakdown of the blood-retina barrier. The anti-HTRA1 technique affords a promising completely different treatment option to moist AMD, complementary to anti-VEGF treatment.
Age-related telomere attrition causes aberrant gene expression in sub-telomeric areas
Telomere attrition has been proposed as a biomarker and causal take into consideration rising older. Together with inflicting cellular senescence and apoptosis, telomere shortening has been found to affect gene expression in subtelomeric areas. Proper right here, we analyzed the distribution of age-related differentially expressed genes from the GTEx RNA sequencing database of 54 tissue kinds from 979 human subjects and positioned significantly additional upregulated than downregulated genes in subtelomeric areas as as compared with the genome-wide frequent. Our information present spatial relationships between telomeres and gene expression in rising older.
WEScover: selection between medical whole exome sequencing and gene panel testing
Background: Total exome sequencing (WES) is extensively adopted in medical and evaluation settings; nonetheless, one among many wise points is the potential false negatives due to incomplete breadth and depth of safety for a variety of exons in clinically implicated genes. In some situations, a targeted gene panel testing may be a dependable risk to find out true negatives for genomic variants in acknowledged disease-associated genes. We developed a web-based instrument to shortly gauge whether or not or not all genes of curiosity may very well be reliably coated by WES or whether or not or not targeted gene panel testing must be thought-about as a substitute for cut back false negatives in candidate genes.
Outcomes: WEScover is a novel web utility that offers an intuitive individual interface for finding breadth and depth of safety all through population-scale WES datasets, searching each by phenotype, by targeted gene panel(s) or by gene(s). Moreover, the making use of reveals metrics from the Genome Aggregation Database to current gene-centric view on breadth of safety.
Conclusions: WEScover permits clients to successfully query genes and phenotypes for the safety of associated exons by WES and recommends use of panel exams for the genes with potential incomplete safety by WES.
